Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd. is a biomedical company engaged in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T) therapies and related products and services. Its offerings include autologous adipose-derived stem cell (ADSC) products for knee osteoarthritis and cartilage defects, cytokine-induced killer cells for various tumors, and dendritic cell-activated cytokine-induced killer cells for solid tumors. The company is conducting a phase 1/2 multicenter study of CD19-targeted CAR-T therapy in patients with relapsed or refractory B-cell lymphoma, as well as a follow-up study of lentiviral-based gene-modified immune cell therapy. Founded in 2017, it is based in Taipei, Taiwan.